IRIS
JAFFRAIN, MARIE LISE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.489
AS - Asia 2.824
EU - Europa 2.818
SA - Sud America 294
Continente sconosciuto - Info sul continente non disponibili 128
AF - Africa 42
OC - Oceania 12
Totale 11.607
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.401
SG - Singapore 1.137
IE - Irlanda 662
CN - Cina 615
RU - Federazione Russa 538
IT - Italia 357
TR - Turchia 320
SE - Svezia 304
VN - Vietnam 295
HK - Hong Kong 272
DE - Germania 251
BR - Brasile 245
GB - Regno Unito 198
UA - Ucraina 176
FR - Francia 131
FI - Finlandia 102
CA - Canada 52
BD - Bangladesh 32
IN - India 26
JP - Giappone 26
BE - Belgio 22
MX - Messico 20
ES - Italia 19
NL - Olanda 15
CZ - Repubblica Ceca 14
IQ - Iraq 14
AR - Argentina 13
VE - Venezuela 12
AU - Australia 10
DZ - Algeria 9
ID - Indonesia 9
KR - Corea 9
SA - Arabia Saudita 9
PK - Pakistan 8
ZA - Sudafrica 8
EU - Europa 7
IL - Israele 7
KZ - Kazakistan 7
MA - Marocco 7
EC - Ecuador 6
TN - Tunisia 6
AE - Emirati Arabi Uniti 5
AT - Austria 5
CO - Colombia 5
CR - Costa Rica 5
PL - Polonia 5
PY - Paraguay 5
UY - Uruguay 5
KE - Kenya 4
LT - Lituania 4
NP - Nepal 4
AL - Albania 3
JO - Giordania 3
LB - Libano 3
MY - Malesia 3
PT - Portogallo 3
UZ - Uzbekistan 3
BH - Bahrain 2
KH - Cambogia 2
MD - Moldavia 2
NZ - Nuova Zelanda 2
PA - Panama 2
PR - Porto Rico 2
PS - Palestinian Territory 2
SC - Seychelles 2
TT - Trinidad e Tobago 2
AO - Angola 1
BF - Burkina Faso 1
BZ - Belize 1
CL - Cile 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
EG - Egitto 1
GE - Georgia 1
GN - Guinea 1
GP - Guadalupe 1
GY - Guiana 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
IR - Iran 1
IS - Islanda 1
JM - Giamaica 1
KG - Kirghizistan 1
LK - Sri Lanka 1
MK - Macedonia 1
ML - Mali 1
MM - Myanmar 1
MN - Mongolia 1
NI - Nicaragua 1
NO - Norvegia 1
PE - Perù 1
PH - Filippine 1
QA - Qatar 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
Totale 11.487
Salva come PNG Salva come JPEG
Città #
Jacksonville 702
Chandler 682
Singapore 681
Dublin 662
San Jose 508
Dallas 389
Ashburn 342
Hong Kong 268
Boardman 267
Santa Clara 266
Council Bluffs 219
The Dalles 159
Izmir 148
New York 132
Nanjing 124
San Mateo 124
L’Aquila 114
Moscow 109
Wilmington 103
Lawrence 98
Princeton 98
Ho Chi Minh City 84
Ann Arbor 80
Lauterbourg 72
Beijing 61
Hanoi 60
Milan 52
Dong Ket 48
Los Angeles 43
Des Moines 40
Nanchang 39
Hefei 38
São Paulo 35
Woodbridge 34
Dearborn 33
Shenyang 30
L'aquila 29
Munich 29
Verona 28
Hebei 27
Mountain View 25
Seattle 25
Jiaxing 24
Tokyo 24
Kunming 23
San Francisco 23
Tianjin 22
Toronto 22
Brussels 20
Frankfurt am Main 20
Rome 20
Brooklyn 19
Columbus 18
Helsinki 18
Guangzhou 17
Orem 16
Shanghai 14
Changsha 13
Jinan 13
Montreal 11
Atlanta 10
Brno 10
Mexico City 10
Ningbo 10
Norwalk 9
Buffalo 8
Falkenstein 8
Falls Church 8
Haiphong 8
Houston 8
London 8
Philadelphia 8
Pune 8
Zhengzhou 8
Biên Hòa 7
Caracas 7
Charlotte 7
Da Nang 7
Phoenix 7
Rio de Janeiro 7
Stockholm 7
Baghdad 6
Changchun 6
Ninh Bình 6
Washington 6
Bremen 5
Miami 5
Montevideo 5
Mumbai 5
Nuremberg 5
Padova 5
Paris 5
Pescara 5
Taizhou 5
Amsterdam 4
Capistrello 4
Chengdu 4
Curitiba 4
Dhaka 4
Fremont 4
Totale 7.707
Salva come PNG Salva come JPEG
Nome #
AHR over-expression in papillary thyroid carcinoma: clinical and molecular assessments in a series of Italian acromegalic patients with a long-term follow-up. 188
18F-DOPA PET/CT Physiological Distribution and Pitfalls: Experience in 215 Patients 176
The R304X mutation of the Aryl hydrocarbon receptor Interacting Protein (AIP) gene in familial isolated pituitary adenomas: mutational Hot-Spot or founder effect? 167
L'acromégalie familiale: A propos d'une observation, revue de la littérature 159
X-linked acrogigantism syndrome: Clinical profile and therapeutic responses 158
Le forme familiari di adenoma ipofisario 145
p16 (INK4a, MTS-1) gene polymorphism and methylation status in human pituitary tumors 141
15 year-old boy with ocular palsy and headache. Invasive macroprolactinoma 136
Contenuto dei grassi nella dieta e rischio di insorgenza di carcinoma della mammella. 133
Clinical and genetic characterization of pituitary gigantism: An international collaborative study in 208 patients 130
Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pitutuitary adenomas: pathological and clinical implications 128
T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly 128
Expression of Peroxisome Proliferator-Activated Receptor alpha (PPARα) in somatotropinomas: Relationship with Aryl hydrocarbon receptor Interacting Protein (AIP) and in vitro effects of fenofibrate in GH3 cells 127
High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. 126
How to Classify Pituitary Neuroendocrine Tumors (PitNET)s in 2020 126
Fractionated stereotactic radiotherapy for large and invasive non-functioning pituitary adenomas: long-term clinical outcomes and volumetric MRI assessment of tumor response. 123
Downregulation of miR-410 targeting the cyclin B1 gene plays a role in pituitary gonadotroph tumors 123
A Study of Alternative TrkA Splicing Identifies TrkAIII as a Novel Potentially Targetable Participant in PitNET Progression 122
Two familial giant pituitary adenomas associated with overweight: clinical, morphological and genetic features 119
A constitutive active MAPK/ERK pathway due to BRAFV600E positively regulates AHR pathway in PTC 118
Hypophysitis 118
Mutations in the aryl hydrocarbon receptor interacting protein gene are not highly prevalent among subjects with sporadic pituitary adenomas 117
From resistant to aggressive and malignant prolactinomas: a translational approach 117
HMGA1-pseudogene expression is induced in human pituitary tumors 117
Hypophysitis and Granulomatous Pituitary Lesions in Systemic Diseases 117
Clinical characterization of familial isolated pituitary adenomas 116
Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene Mutations in Familial Isolated Pituitary Adenomas: Analysis in 73 Families 115
Aggressive prolactinoma in a child related to germline mutation in the Aryl hydrocarbon receptor Interacting Protein (AIP) gene. 115
New insights in the pathogenesis of pituitary tumours 115
Impact of successful transsphenoidal surgery on cardiovascular risk factors in acromegaly 113
Marked improvement in cardiovascular function after successful transsphenoidal surgery in acromegalic patients 113
Hyperplasia-adenoma sequence in pituitary tumorigenesis related to Aryl hydrocarbon receptor Interacting Protein gene mutation. 112
Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. 112
Expression of Peroxisome Proliferator-Activated Receptor Alpha (PPARα) in Non-Somatotroph Pituitary Tumours and the Effects of PPARα Agonists on MMQ Cells 112
Salivary gland tissues and derived primary and metastatic neoplasms: unusual pitfalls in the work-up of sellar lesions. A systematic review 112
Diagnosis and management of pituitary tumours in the elderly: a review based on personal experience and evidence of literature 111
Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy inpatients with prolactin-secreting pituitary adenomas 111
Effects of gonadal steroids on the growth of human pituitary adenomas in vitro 110
Macroprolactinomas as a cause of delayed puberty: a report of two cases and effects of medical therapy 110
A critical re-appraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas 110
Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations. 110
Immunotherapy for Aggressive and Metastatic Pituitary Neuroendocrine Tumors (PitNETs): State-of-the Art 109
Beta-interferon, retinoids and tamoxifen as maintenance therapy in metastatic breast cancer. A pilot study 108
The Role of Aryl Hydrocarbon Receptor (AHR) and AHR-Interacting Protein (AIP) in the Pathogenesis of Pituitary Adenomas 108
Are aggressive pituitary tumors and carcinomas two sides of the same coin? Pathologists reply to clinician’s questions 108
Comparison of six-months therapy with octreotide versus lanreotide in acromegalic patients: a retrospective study 107
Acute effects of octreotide, cabergoline and a combination of both drugs on GH secretion in acromegalic patients 107
Clinical and genetic features of familial pituitary adenomas 107
Biochemical remission and recurrence rate of secreting pituitary adenomas after transsphenoidal adenomectomy: long-term endocrine follow-up results 106
Relationship between blood pressure and glucose tolerance in acromegaly 106
Alternative Lengthening of Telomeres (ALT) and Telomerase Reverse Transcriptase Promoter Methylation in Recurrent Adult and Primary Pediatric Pituitary Neuroendocrine Tumors 106
The genetics of pituitary adenomas 105
Stereotactic reirradiation with temozolomide in patients with recurrent aggressive pituitary tumors and pituitary carcinomas 105
Cardiac effects of SR-Lanreotide, a slow-release somatostatin analog, in acromegalic patients 104
Prevalence of hypertension in acromegalic patients: clinical measurement versus 24-hour ambulatory blood pressure monitoring 104
Expression of Epidermal Growth Factor in neoplastic pituitary cells: evidence for a role in corticotrophinoma cells 103
Genetic susceptibility in pituitary adenomas: from pathogenesis to clinical implications 103
Il ruolo dell'endocrinologo nel trattamento delle lesioni della regione sellare 103
Cyclin-dependent kinase inhibitor 1B (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenoma kindreds. 103
Familial pituitary adenomas. 102
Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database 101
The prevalence of silent acromegaly in prolactinomas is very low 101
Echocardiographic evidence for a direct effect of GH/IGF-I hypersecretion on cardiac mass and function in young acromegalics 100
Infusione sequenziale di GHRH 1-29NH2, LHRH e TRH per la valutazione della riserva ipofisaria: confronto con il Politest. 100
A multivariable prediction model for pegvisomant dosing: Monotherapy and in combination with long-acting somatostatin analogues 100
Influence of radiotherapy on long-term follow-up of clinically non-secreting pituitary adenomas 99
De la génétique des adénomes hypophysaires 99
Prognostic Factors: Molecular Pathway – Tumour Suppressor Gene (MEN1) 98
Familial pituitary adenomas: from clinical practice to basic research 97
A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) proposal 97
Effect of 17β-estradiol, progesterone and tamoxifen on in vitro proliferation of human pituitary adenomas. Correlation with specific cellular receptors 96
Surgical treatment and clinical outcome of GH-secreting adenomas in elderly patients 95
Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients 92
HPLC determination of urinary catecholamines as a screening test for pheochromocytoma in a patient with medullary carcinoma of the thyroid. 92
Two-year follow-up of acromegalic patients treated with slow release Lanreotide (30 mg) 91
Evaluation of the adequacy of Levothyroxine replacement therapy in patients with central hypothyroidism 91
Pituitary neuroendocrine tumors (PitNETs): nomenclature evolution, not clinical revolution 91
Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly 91
Sellar and parasellar lesions in the transition age: a retrospective Italian multi-centre study 90
Human pituitary tumours express the bHLH transcription factors NeuroD1 and ASH1 90
Somatic mosaicism underlies X-linked acrogigantism syndrome in sporadic male subjects 90
The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas 89
Pituitary adenomas in young patients: when should we consider a genetic predisposition? 89
Sleep Disorders in Patients With Craniopharyngioma: A Physiopathological and Practical Update 89
Radiotherapy for nonfunctioning pituitary adenomas: from conventional to modern stereotactic radiation techniques. 88
Cellular receptors for sex steroids in human pituitary adenomas 86
Prevalence of silent acromegaly in prolactinomas (PASP): an Italian experience 86
Variable pathological and clinical features of a large Brazilian family harboring a mutation in the aryl hydrocarbon receptor-interacting protein gene 85
Clinical and Molecular Characteristics of Gonadotroph Pituitary Tumors According to the WHO Classification 85
Ageing and pituitary neuroendocrine tumours (PitNETs): from bench to bedside 84
Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. 84
Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter study. 84
Germline loss-of-function PAM variants are enriched in subjects with pituitary hypersecretion 83
Epidermal growth factor (EGF)- binding sites in human pituitary adenomas 83
Evolving criteria for post-operative biochemical remission of acromegaly: can we achieve a definitive cure ? An audit of surgical results on a large series and a review of the literature 83
Fenofibrate has differential effects on cell proliferation and GH secretion in GH3 cells 83
Long-term follow-up results of postoperative radiation therapy for Cushing's disease 82
Surgical treatment of pituitary tumours in the elderly: clinical outcome and long-term follow-up 82
Visual improvement during octreotide therapy in a case of episellar meningioma 80
Giant prolactinomas presenting as skull base tumors 79
Totale 10.765
Salva come PNG Salva come JPEG
Categoria #
all - tutte 50.476
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 50.476
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022586 0 0 120 35 36 7 5 44 37 7 33 262
2022/20231.879 136 112 74 173 163 215 2 116 792 5 64 27
2023/2024528 159 29 19 69 33 136 9 13 2 15 12 32
2024/20251.826 47 27 180 35 292 148 223 176 383 61 155 99
2025/20263.573 137 342 267 294 302 268 713 185 313 379 324 49
2026/2027400 101 265 34 0 0 0 0 0 0 0 0 0
Totale 11.607